Telios offers investors their money back

Telios offers investors their money back

Telios Pharmaceuticals Inc. on Friday authorized the repurchase of the 3 million convertible preferred shares, which it had offered on Sept. 29, in the wake of disappointing results in its second clinical trial of Argidene Gel

Read the full 425 word article

How to gain access

Continue reading with a
two-week free trial.